Glycoengineering of pertuzumab and its impact on the pharmacokinetic/pharmacodynamic properties
Sign Up to like & getrecommendations! Published in 2017 at "Scientific Reports"
DOI: 10.1038/srep46347
Abstract: Pertuzumab is an antihuman HER2 antibody developed for HER2 positive breast cancer. Glycosylation profiles are always the important issue for antibody based therapy. Previous findings have suggested the impact of glycosylation profiles on the function… read more here.
Keywords: pharmacodynamic properties; glycoengineering pertuzumab; sialic acid; pharmacokinetic pharmacodynamic ... See more keywords